Channel Therapeutics Corporation (CHRO)
NYSEAMERICAN: CHRO · Real-Time Price · USD
0.631
-0.009 (-1.37%)
Dec 24, 2024, 12:59 PM EST - Market closed
Company Description
Channel Therapeutics Corporation, a clinical-stage biotech company, focuses on the development and commercialization of new therapeutics to alleviate pain.
The company intends to selectively target the sodium ion-channel known as NaV1.7, as well as other receptors in the NaV family.
Its lead compound comprises CC8464, which is in Phase 2a clinical trials for use in the treatment of erythromelalgia, as well as other fields of neuropathic pain and acute and chronic eye pain.
The company was Chromocell Therapeutics Corporation and changed its name to Channel Therapeutics Corporation in November 2024.
Channel Therapeutics Corporation was founded in 2002 and is based in Freehold, New Jersey.
Channel Therapeutics Corporation
| Country | United States |
| Founded | 2002 |
| IPO Date | Feb 16, 2024 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 8 |
| CEO | Francis Knuettel |
Contact Details
Address: 4400 Route 9 South, Suite 1000 Freehold, New Jersey 07728 United States | |
| Phone | 877 265 8266 |
| Website | chromocell.com |
Stock Details
| Ticker Symbol | CHRO |
| Exchange | NYSEAMERICAN |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $6.00 |
| CIK Code | 0001919246 |
| ISIN Number | US1711261057 |
| Employer ID | 86-3335449 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Francis Knuettel II, M.B.A. | President, Chief Executive Officer, Chief Financial Officer, Treasurer, Secretary and Director |
| Dr. Eric Lang M.D. | Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 19, 2024 | EFFECT | Notice of Effectiveness |
| Dec 11, 2024 | POS AM | Post-Effective amendments for registration statement |
| Dec 2, 2024 | EFFECT | Notice of Effectiveness |
| Nov 22, 2024 | POS AM | Post-Effective amendments for registration statement |
| Nov 22, 2024 | POS AM | Post-Effective amendments for registration statement |
| Nov 21, 2024 | 8-K | Current Report |
| Nov 19, 2024 | 8-K12G3 | Filing |
| Nov 18, 2024 | 8-K | Current Report |
| Nov 13, 2024 | 424B3 | Prospectus |
| Nov 13, 2024 | 424B3 | Prospectus |